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Summary. The effects of pretransplant herpes virus sero- 
logy on the occurrence of grades I I - IV  acute graft- 
versus-host disease (GVHD) were studied in 262 recipi- 
ents and their HLA-identical family donors. In 131 recipi- 
ents on standard GVHD prophylaxis (either methotrexate 
or cyclosporin A) significant effects were observed for 
donor HSV serology (seropositivity associated with in- 
creased risk for GVHD) and donor EBV serology (sero- 
negativity associated with increased risk). However, these 
effects were nonsignificant in the other 131 recipients on 
intensified GVHD prophylaxis (i.e., methotrexate com- 
bined with cyclosporin A, in vivo anti-T-cell monoclonal 
antibodies, or various procedures to reduce the T-cell 
numbers in the transplants). 
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Introduction 
The incidence and severity of acute graft-versus-host dis- 
ease (GVHD) can be reduced by removing the bacterial 
microflora from the gastrointestinal tracts of animals [1] 
and human beings [11]. The potentiating effect of the 
gastrointestinal microflora on graft-versus-host reactivity 
may occur via the activation of lymphocytes or their pre- 
cursors during the immediate post-transplant period. 
Similar effects may be mediated by viruses and parasites 
carried by the recipients at the time of transplantation 
[6]. Herpes viruses are important candidates ince they 
establish life-long carrier status after initial infection and 
frequently reactivate during immunosuppression. I  ad- 
dition, herpes virus carrier status leads to the develop- 
ment of virus-specific humoral and cellular immunity, so 
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that the presence of virus-specific antibodies may be 
taken as a marker for carrier status and presence of virus- 
specific memory cells. 
Several studies of the effects of pretransplant herpes 
virus serology in allogeneic bone marrow transplant 
(BMT) recipients and their donors on the development of
acute GVHD have been performed (Table 1). Two single- 
center studies [2,7] were followed by a retrospective 
multicenter study of data collected by the European 
Group for Bone Marrow Transplantation [3]. In all stud- 
ies, the risk of grades I I -  IV GVHD increased proportio- 
nally with the number of herpes viruses carried. However, 
results were discordant at the level of individual viruses 
(Table 1). 
In 1986, the two BMT teams in Leiden intensified 
their GVHD prophylactic protocols to reduce GVHD- 
related morbidity and mortality. Around the same time, 
the BMT team in Utrecht embarked on a protocol in 
which T-lymphocyte-depleted bone marrow grafts were 
reconstituted with a fixed low number of T cells prior to 
administration [10]. The present analysis of 262 patients 
who underwent transplantation by these three teams was 
performed to assess the effect of intensification of 
GVHD prophylaxis on the interaction between herpes 
virus carrier status and grades I I - IV  acute GVHD. 
Patients and methods 
Between 1978 and 1991, 262 patients received transplants with bone 
marrow grafts from their HLA-identical siblings in Leiden (Dept. 
of Hematology, n = 126; Dept. of Pediatrics, n = 76) and in Utrecht 
(n = 60). The diagnostic ndications for BMT were severe aplastic 
anemia (n = 28), acute nonlymphoblastic leukemia (n = 120), acute 
lymphoblastic leukemia (n = 50), chronic myelogenous leukemia 
(n = 35), non-Hodgkin's lymphoma (n = 9), Kahler's disease 
(n = 5), other hematological malignancies (n = 8) or other indica- 
tions (n = 7). The median age of the patients was 35 years (range 
10 months to 48 years). Standard GVHD prophylaxis (either metho- 
trexate or cyclosporin A) was given to 131 patients. Intensified 
GVHD prophylaxis was given to the other 131 patients (metho- 
trexate + cyclosporin A, n = 21; in vivo anti-T-cell monoclonal nti- 
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Table 1. Pretransplant herpes virus sero- 
logy and acute GVHD; summary of three 
clinical studies 
Lower risk Higher risk Leiden 1987 Huddinge 1988 EGBMT 1990 
Donor 
0 -2  Viruses 3 -4  Viruses p < 0.05 p < 0.05 p < 0.05 
HSV negative HSV positive p < 0.05 NS NS 
EBV positive EBV negative p < 0.05 NS NS 
Recipient 
0 -2  Viruses 3 -4  Viruses p < 0.05 p < 0.05 p < 0.05 
CMV negative CMV positive NS p < 0.05 NS 
EBV negative EBV positive p <~ 0.05 NS NS 
bodies, n = 23; in vitro T-cell depletion using anti-T-cell monoclonal 
antibodies, n = 28; and fixed low T-cell numbers in the grafts, 
n = 60). All transplants resulted in full engraftment. Four patients 
(three on standard and one on intensified GVHD prophylaxis) were 
excluded from subsequent analyses because they died without clini- 
cal signs of GVHD while being at risk for the disease (i.e., prior to 
day 100 post BMT). 
IgG antibodies against herpes simplex virus (HSV), varicella 
zoster virus (VZV), and Epstein-Barr virus (EBV) capsid antigen 
were detected using indirect immunofluorescence assays, IgG anti- 
bodies against cytomegalovirus (CMV) late antigen by an enzyme- 
linked immunoassay. 
Results 
Grades I I - IV  acute GVHD occurred in 53 of the 128 
patients on standard GVHD prophylaxis (41~ and in 
only 28~ of the 130 patients on intensified GVHD pro- 
phylaxis (22%). First, a multivariate analysis of the inter- 
action between donor and recipient pretransplant herpes 
virus serology and acute GVHD was performed on all 262 
patients. Competing nonvirological factors in the analy- 
sis were chosen on the basis of their significant role in 
previous analyses (Table 2, upper panel) [5, 7]. With re- 
spect to herpes virus serology, significant but opposite 
effects were observed for donor HSV serology (higher 
risk vs. lower risk, seropositive vs. seronegative; p = 0.03) 
and donor EBV serology (higher risk vs. lower risk, sero- 
negative vs. seropositive; p = 0.01) (Table 2, lower panel). 
Separate analysis of patients on standard and intensified 
GVHD prophylaxis revealed that the significant effects of 
donor HSV and EBV serology were confined to the pa- 
tients on standard GVHD prohylaxis; the effects of herpes 
virus serology in the patients on intensified GVHD pro- 
phylaxis were nonsignificant (Table 3). Cross-tabulations 
for the individual viruses are shown in Table 4 (HSV, 
upper panel; EBV, lower panel) and illustrate the disap- 
pearance of the effect of donor HSV and EBV serology 
on acute GVHD. In both patient groups, grades I I - IV  
acute GVHD are rare to absent in the (young) seronega- 
tive recipients of marrow from seronegative donors. 
Table 2. Multivariate analysis on 262 patients 
A. Competing factors in the analysis 
Pre-BMT serology Odds ratio p value 
Intensified prophylaxis for GVHD 
given 0.20 0.0001 
Total GI decontamination 0.24 0.01 
Increasing age, recipient 1.0 NS 
Increasing age, donor 1.0 NS 
Sex mismatch 1.5 NS 
B. Pretransplant herpes virus serology 
Pre-BMT serology Odds ratio p value 
Donor 
HSV positive 2.8 0.03 
CMV positive 1.6 NS 
VZV positive 2.1 NS 
EBV positive 0.3 0.01 
Recipient 
HSV positive 1.0 NS 
CMV positive 1.5 NS 
VZV positive 1.4 NS 
EBV positive 2.6 NS 
Discussion 
We have shown that various protocols of intensified 
GVHD prophylaxis interfere with the effects of pretrans- 
plant herpes virus serology on the occurrence of grades 
I I - IV  acute GVHD. With respect o HSV, we have infer- 
red that HSV-specific memory T lymphocytes in the 
grafts are responsible for the effect [7]. This contention 
is supported by the observation of BostrOm et al. [4] that 
strong donor mononuclear cell reactivity to HSV is as- 
sociated with an increased frequency of grades I I - I I I  
GVHD. Thus, the activation of HSV-specific memory T 
lymphocytes by the HSV-encoded or cross-reactive anti- 
gens in the recipients may contribute to GVHD, possibly 
via the release of cytokines that induce systemic T-cell 
activation. 
The first encounter of T lymphocytes from EBV-sero- 
negative donors with the virus or with EBV-transformed 
cells leads to their polyclonal activation, as observed in 
infectious mononucleosis [9]. Indeed, an increased rate 
of EBV production in the oropharynx has been observed 
in the immediate post-BMT period [8], similar to the 
situation in immunosuppressed renal transplant recipi- 
ents [12]. Again, the depletion or the functional suppres- 
sion of T lymphocytes would prevent heir activation and 
cytokine production. 
Table 3. Effect of intensification f 
GVHD prophylaxis 
A139 
Pre-BMT serology Standard Intensified 
O.R. p value O.R. p value 
Donor 
HSV positive 5.4 0.007 1.2 NS 
CMV positive 3.4 0.03 1.1 NS 
VZV positive 2.2 NS 2.1 NS 
EBV positive 0.08 0.002 0.8 NS 
Recipient 
HSV positive 2.6 NS 0.7 NS 
CMV positive 1.1 NS 1.9 NS 
VZV positive 2.0 NS 1.1 NS 
EBV positive 6.0 0.05 1.1 NS 
Table 4. Effects of intensification f 
GVHD prophylaxis 
A. Pretransplant HSV serology and acute GVHD 
Pre-BMT serology Standard Intensified 
Recipient Donor Gr. 0 -  I Gr. I I -  IV Gr. 0 -  I Gr. I I -  IV 
Negative Negative 11 1 (8%) 12 0 (0%) 
Negative Positive 10 2 (17%) 7 4 (36%) 
Positive Negative 19 5 (21%) 10 6 (38%) 
Positive Positive 35 45 (56%) 73 18 (20%) 
B. Pretransplant EBV serology and acute GVHD 
Pre-BMT serology Standard Intensified 
Recipient Donor Gr. 0 - I  Gr. I I - IV  Gr. 0 - I  Gr. I I - IV  
Negative Negative 11 2 (15o70) 4 0 (0%) 
Negative Positive 9 1 (10%) 6 2 (25%) 
Positive Negative 4 10 (71%) 6 2 (25%) 
Positive Positive 51 40 (44%) 86 24 (22%) 
T lymphocytes constitute the final common pathway 
through which GVHD is effectuated. This study shows 
that the depletion of T lymphocytes from the marrow 
grafts or the prevention of their activation post BMT 
abolishes the significance of pretransplant herpes virus 
serology as a risk factor for grades I I - IV  acute GVHD. 
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